Giant Biogene (02367.HK) Hong Kong Stock Hot Stock Analysis Report

Giant Biogene (02367.HK) is a Hong Kong-listed medical aesthetics/skincare enterprise and a leader in the recombinant collagen industry. Its brands such as “Kefumei” and “Keligold” have high popularity in the domestic market [0][2].
The company made it to the East Money App Hong Kong Stock Popularity Ranking on December 25, 2025. The core catalyst was the plan announced on December 3 to repurchase no more than 104 million shares (10% of issued shares), which demonstrates management’s confidence in the company’s long-term development; meanwhile, the company communicated its 2026 strategic plans (including product matrix expansion, brand operation, and channel expansion) with the capital market, further strengthening market attention to its long-term growth potential [2][3].
As the Hong Kong stock market was closed on December 25-26, 2025 [4], there is no latest transaction price and volume data available. Previous market trends showed that the company’s stock price has adjusted recently due to the sales pressure of its core brand “Kefumei” during the Double 11 period [3]; after the repurchase plan was announced, the stock price showed signs of short-term stabilization amid adjustments [2][3].

1. Institutional Sentiment Divided but Long-Term Confidence Firm
   : CICC maintained the “Outperform Industry” rating [2], and CMB International maintained the “Buy” rating [3], both believing that the repurchase plan reflects management’s confidence and the company’s long-term competitive advantages are solid; China Merchants Securities downgraded the rating to “Neutral” [1], taking a cautious attitude towards the short-term outlook for 2026, but also pointed out that the stock price has basically digested negative factors.
2. Retail Investor Attention Increased Significantly
   : The company’s stock made it to the East Money App Hong Kong Stock Popularity Ranking, reflecting retail investors’ expectations for the launch of its new products in 2026 and the effects of channel adjustments [0].
3. Repurchase Plan Infuses Confidence into the Market
   : Against the backdrop of intensified industry competition and short-term sales pressure on core brands, the large-scale repurchase plan conveys management’s recognition of the company’s intrinsic value to the market [2][3].

• As a leader in the recombinant collagen industry, the company has core technological advantages, and the industry has huge growth potential [0][2].
• The 2026 strategic plans such as product matrix expansion, brand operation optimization, and channel expansion are expected to drive the company’s long-term performance growth [2][3].

• Short-term Sales Pressure
  : The core brand “Kefumei” saw a sales decline during the Double 11 period, facing challenges such as the fading of traffic dividends and intensified competition in the single-use category [3].
• Brand Reputation Risk
  : It has faced a series of reputation crises, and there is uncertainty about whether it can retain its customer base and restore brand strength [1].
• Industry Competition
  : The skincare and medical aesthetics industries are highly competitive, and there is uncertainty about the progress of new product launches and market acceptance [2].
• Impact of Market Closure
  : Due to the Christmas market closure, the market reaction may lag until December 29 (the next full trading day) [4].

• Core catalyst for the hot stock: 10% share repurchase plan and 2026 strategic plan announced on December 3, 2025.
• Market status: Hong Kong stock market closed on December 25-26, 2025; no latest transaction price and volume data available [4].
• Market sentiment: Institutional sentiment divided; retail investor attention increased significantly.
• Reference prices: CICC target price HK$56 [2]; China Merchants Securities target price HK$34.5 [1]; CMB International target price HK$53.89 [3].